Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: A retrospective cohort study in a single institution

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Ogura, Kengo ^a   Mizowaki, Takashi ^a   Arakawa, Yoshiki ^b   Ogura, Masakazu ^a   Sakanaka, Katsuyuki ^a   Miyamoto, Susumu ^b   Hiraoka, Masahiro ^a  

^a Departments of Radiation Oncology and Image applied Therapy   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Glioblastoma; Radiotherapy; RANO criteria; Recurrence patterns; Salvage treatment; Temozolomide

Indexed keywords

TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE COURSE; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; PRESCRIPTION; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; COHORT STUDIES; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 84876698243     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-97     Document Type: Article

References (20)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996. 10.1056/NEJMoa043330, 15758009.
2. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncology: Official J Am Soc Clin Oncology 1990, 8:1277-1280.
3. Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 2008, 29:419-424. 10.3174/ajnr.A0963, 18272557.
4. Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK. Response criteria for glioma. Nat Clin Pract Oncol 2008, 5:634-644. 10.1038/ncponc1204, 18711427.
5. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncology: Official J Am Soc Clin Oncology 2009, 27:2905-2908.
6. Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amista P, Morandi L, Spagnolli F, Ermani M. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncology: Official J Am Soc Clin Oncology 2009, 27:1275-1279.
7. Milano MT, Okunieff P, Donatello RS, Mohile NA, Sul J, Walter KA, Korones DN. Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 2010, 78:1147-1155. 10.1016/j.ijrobp.2009.09.018, 20207495.
8. Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, Lanzetta G, Scarpino S, Arcella A, Enrici RM. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 2010, 97:377-381. 10.1016/j.radonc.2010.08.020, 20855119.
9. McDonald MW, Shu HK, Curran WJ, Crocker IR. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys 2011, 79:130-136. 10.1016/j.ijrobp.2009.10.048, 20399036.
10. Dobelbower MC, Burnett Iii OL, Nordal RA, Nabors LB, Markert JM, Hyatt MD, Fiveash JB. Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. J Med Imaging Radiat Oncol 2011, 55:77-81. 10.1111/j.1754-9485.2010.02232.x, 21382192.
11. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncology: Official J Am Soc Clin Oncology 2010, 28:1963-1972.
12. Ghose A, Lim G, Husain S. Treatment for glioblastoma multiforme: current guidelines and Canadian practice. Curr Oncol 2010, 17:52-58. 2993441, 21151410.
13. Shibamoto Y, Yamashita J, Takahashi M, Yamasaki T, Kikuchi H, Abe M. Supratentorial malignant glioma: an analysis of radiation therapy in 178 cases. Radiother Oncol 1990, 18:9-17. 10.1016/0167-8140(90)90018-R, 2163064.
14. Shibamoto Y, Nishimura Y, Tsutsui K, Sasai K, Takahashi M, Abe M. Comparison of accelerated hyperfractionated radiotherapy and conventional radiotherapy for supratentorial malignant glioma. Jpn J Clin Oncol 1997, 27:31-36. 10.1093/jjco/27.1.31, 9070338.
15. Chang EL, Akyurek S, Avalos T, Rebueno N, Spicer C, Garcia J, Famiglietti R, Allen PK, Chao KS, Mahajan A, Woo SY, Maor MH. Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 2007, 68:144-150. 10.1016/j.ijrobp.2006.12.009, 17306935.
16. Aoki T, Mizutani T, Nojima K, Takagi T, Okumura R, Yuba Y, Ueba T, Takahashi JA, Miyatake S, Nozaki K, Taki W, Matsutani M. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme. J Neurosurg 2010, 112:50-56. 10.3171/2009.5.JNS081738, 19538050.
17. Topkan E, Topuk S, Oymak E, Parlak C, Pehlivan B. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. Am J Clin Oncol 2012, 35:284-289. 10.1097/COC.0b013e318210f54a, 21399487.
18. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008, 9:453-461. 10.1016/S1470-2045(08)70125-6, 18452856.
19. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, van Es CA, van den Bent MJ. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008, 113:405-410. 10.1002/cncr.23562, 18484594.
20. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncology: Official J Am Soc Clin Oncology 2008, 26:2192-2197.